MedTrace Logo

Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy

NCT07336797 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-01-13

No results posted yet for this study

Summary

We investigate the role of empagliflozin in the treatment of obesity in PLWH.

Conditions

  • Metabolic Syndrome
  • Obesity & Overweight
  • HIV (Human Immunodeficiency Virus)

Interventions

DRUG

Empagliflozin (oral)

Empagliflozin is an oral medication used primarily to treat type 2 diabetes. It belongs to a class of drugs called SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors). Empagliflozin blocks SGLT2 proteins in the kidneys. This prevents glucose reabsorption, causing excess sugar to be excreted in urine. It helps lower blood sugar levels and can also reduce body weight and blood pressure.

DRUG

Placebo

TDF/FTC+DLG

Sponsors & Collaborators

  • Abdelrahman Mahmoud

    lead OTHER

Principal Investigators

  • Maggie Abbassi, Prof. · Cairo University

  • Abedalrahman Dosoky · Cairo University

  • Ahmed Kamel · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2026-12-30
Completion
2027-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07336797 on ClinicalTrials.gov